Antibiotics for community acquired pneumonia in adult outpatients
- 19 April 2004
- reference entry
- Published by Wiley
- No. 2,p. CD002109
- https://doi.org/10.1002/14651858.cd002109.pub2
Abstract
Community‐acquired pneumonia (CAP) is a common condition representing a significant disease burden for the community, particularly for the elderly. Because antibiotics are helpful in treating CAP, they are the standard treatment and CAP thus contributes significantly to antibiotic use, which is associated with the development of bacterial resistance and side‐effects. Although several studies have been published concerning CAP and its treatment, the available data arises mainly from studies conducted in hospitalized patients and outpatients. There is no concise summary of the available evidence that can help clinicians in choosing the most appropriate antibiotic. To summarize the evidence currently available from randomized controlled trials (RCTs) concerning the efficacy of alternative antibiotic treatments for CAP in ambulatory patients above 12 years of age. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2003, issue 2) which contains the Cochrane Acute Respiratory Infections Groups Specialized Register; MEDLINE (January 1966 to September week 3, 2003), and EMBASE (January 1974 to March 2003). We included all randomized controlled trials (RCTs) in which one or more antibiotics were tested for the treatment of CAP in ambulatory adolescent or adult patients. Studies testing one or more antibiotic and reporting the diagnostic criteria used in selecting patients as well as the clinical outcomes achieved were included. No language restrictions were applied. Data were extracted and study reports assessed by two independent reviewers (LMB and TJMV). Authors of studies were contacted as needed to resolve any ambiguities in the study reports. The data were analyzed using the Cochrane Collaboration's RevMan 4.2.2 Software. Differences between reviewers were resolved by discussion and consensus. Three randomized controlled trials involving a total of 622 patients aged 12 years and older diagnosed with community acquired pneumonia were included. The quality of the studies and of the reporting was variable. A variety of clinical, radiological and bacteriological diagnostic criteria and outcomes were reported. Overall there was no significant difference in the efficacy of the various antibiotics under study. Currently available evidence from RCTs is insufficient to make evidence‐based recommendations for the choice of antibiotic to be used for the treatment of community acquired pneumonia in ambulatory patients. Pooling of study data was limited by the very low number of studies. Individual study results do not reveal significant differences in efficacy between various antibiotics and antibiotic groups. Multi‐drug comparisons using similar administration schedules are needed to provide the evidence necessary for practice recommendations.Keywords
This publication has 42 references indexed in Scilit:
- Practice Guidelines for the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2000
- Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia: An Evidence-Based Update by the Canadian Infectious Diseases Society and the Canadian Thoracic SocietyClinical Infectious Diseases, 2000
- Randomized, Multicentre Study of the Efficacy and Tolerance of Azithromycin versus Clarithromycin in the Treatment of Adults with Mild to Moderate Community-Acquired PneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Ofloxacin Once Daily versus Twice Daily in Community-Acquired Pneumonia and Acute Exacerbation of Chronic BronchitisChemotherapy, 1996
- A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practiceDiagnostic Microbiology and Infectious Disease, 1992
- Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infectionsDiagnostic Microbiology and Infectious Disease, 1992
- Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumoniaInfection, 1992
- The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unitRespiratory Medicine, 1992
- Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infectionsDiagnostic Microbiology and Infectious Disease, 1991